The Janus-faced role of KDM5B heterogeneity in melanoma: differentiation as a situational driver of both growth arrest and drug-resistance
Heike Chauvistré(Vrije Universiteit Brussel), Alexander Roesch(University of Regensburg), Ivelina Spassova(German Cancer Research Center), Stefanie Löffek(University Medical Center Freiburg), Renáta Váraljai(Vrije Universiteit Brussel), Susanne Horn(Vrije Universiteit Brussel), Samantha J. Stehbens(The University of Queensland), Felix C. E. Vogel(German Cancer Research Center), Batool Shannan(Vrije Universiteit Brussel), Markus Kaiser(University of Duisburg-Essen), Meenhard Herlyn(The Wistar Institute), Dirk Schadendorf(University of Mannheim), Iris Helfrich(West German Heart and Vascular Center Essen), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kirujan Jeyakumar(TU Dortmund University), Oliver Keminer(Fraunhofer Institute for Translational Medicine and Pharmacology), Annette Paschen(University of Duisburg-Essen), Marc Remke(Düsseldorf University Hospital), Sheraz Gul(Fraunhofer Institute for Translational Medicine and Pharmacology), Nikolas K. Haass(The University of Queensland), Sven Rahmann(University of Duisburg-Essen), Stefanie Egetemaier, Linda Kubat(Essen University Hospital), Sabrina Ninck(University of Duisburg-Essen), Jürgen C. Becker(German Cancer Research Center), Min Xiao(The First Affiliated Hospital, Sun Yat-sen University), Daniel Rauh(TU Dortmund University), Farnusch Kaschani(University of Duisburg-Essen), Michael Ehrmann(University of Duisburg-Essen), Daniel Picard(Heidelberg University), Vito W. Rebecca(The Wistar Institute), Qin Liu(Shengli Oilfield Central Hospital), Xiangfan Yin(The Wistar Institute), Robert J. Ju(The University of Queensland), Sheena M. Daignault(The University of Queensland), Antonio Sechi(RWTH Aachen University)
Unknown
April 1, 2020
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
|Cell|2018|1.4k
Colorectal carcinoma antigens detected by hybridoma antibodies
|Somatic Cell and Molecular Genetics|1979|1.4k
A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas
|Cancer Research|2005|1.3k